A systematic review and meta-analysis suggests that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may be associated with protective effects for patients with COVID-19. The analysis included 52 studies that evaluated clinical outcomes among 101 949 total patients, of whom 26.0% were receiving ACEIs or ARBs. When adjusted for covariates, significant reductions in the risk of death (adjusted odds ratio [aOR], 0.57) and severe adverse events (AEs, aOR, 0.68) were found. Unadjusted and adjusted analyses of a subgroup of patients with high blood pressure indicated decreases in the risk of death (unadjusted OR, 0.66; aOR, 0.51) and severe AEs (unadjusted OR, 0.70; aOR, 0.55). The findings are consistent with previous meta-analysis in patients with high blood pressure, extend to patients with multiple mixed comorbidities, and support the recommendations of medical societies to continue receiving ACEIs and ARBs for patients with COVID-19. Source: https://jamanetwork.com/
A US prospective study found that moderate egg consumption was associated with a significantly lower…
Anxiety disorders are common yet often underrecognized in primary care, but a review shows that…
Two-dose recombinant zoster vaccination (RZV) was associated with a significantly lower risk of new-onset dementia,…
A 13-year follow-up of a randomized controlled trial found that a single colonoscopy screening significantly…
Higher consumption of ultra-processed foods (UPFs) is associated with poorer attention and increased modifiable dementia…
Blood pressure (BP)-lowering treatment significantly reduces the risk of major cardiovascular events in individuals with…
This website uses cookies.